Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-01-2017 | Retinal Disorders

Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration

Authors: Nathalie Massamba, Ali Dirani, Nathalie Butel, Christine Fardeau, Bahram Bodaghi, April Ingram, Phuc Lehoang

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 1/2017

Abstract

Purpose

To evaluate the changes of outer retinal tubulations (ORTs) as seen on spectral-domain optical coherence tomography (SD OCT) in eyes with neovascular age-related macular degeneration (AMD) where treatment was switched from intravitreal ranibizumab to intravitreal aflibercept.

Methods

This was a prospective study of eyes diagnosed with neovascular AMD and previously treated with >6 intravitreal ranibizumab injections and switched to aflibercept, conducted at a single centre (Department of Ophthalmology at Pitié Salpetriere Hospital, Paris VI University) from January to July 2015. Before and after treatment was switched from ranibizumab to aflibercept, SD-OCT was used to evaluate the presence of ORTs. Additional assessments in this patient group included best-corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICGA). Changes in pigment epithelium detachments (PED), presence of intraretinal cysts, and presence of subretinal fluid (SRF) were also noted.

Results

Twenty-four eyes of 24 consecutive patients (15 female/nine male, mean age 70 years) diagnosed with neovascular AMD and previously treated with >6 intravitreal ranibizumab injections and switched to aflibercept were included in the analysis. After receiving aflibercept, patients were followed for a mean of 6.1 months. Prior to treatment switch, 97 % of eyes showed ORTs, while after treatment switch to aflibercept, at the end of the study period, 75 % had ORTs (p = 0.219). Changes in BCVA (LogMAR) were not statistically significant (1.16 ± 0.44 to 1.18 ± 1.06, p = 0.12), however, a significant reduction in central macular thickness (CMT) (from 406 μm ± 112 to 263 μm ± 68, p = 0.001), PED (from 70.8 % to 41.7 % , p = 0.016), presence of intraretinal cysts (from 83.3 % to 33.3 %, p = 0.002) and SRF (from 91.7 % to 25 %, p = 0.001 ) were noted.

Conclusion

After switching from ranibizumab treatment to aflibercept, ORTs remained present in 75 % of eyes, and significant reductions in CMT, PED, and SRF, and presence of intraretinal cysts were observed.

Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J, Eye Diseases Prevalence Research Group (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122(4):564–572CrossRefPubMed

Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I (2008) The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115(1):116–126CrossRefPubMed

Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37(5):855–868PubMed

Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O’Neill CA, Miller JW (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120(3):338–346CrossRefPubMed

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431CrossRefPubMed

Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145(2):239–248. doi:10.1016/j.ajo.2007.10.004 CrossRefPubMed

Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150(3):315.e1–324.e1. doi:10.1016/j.ajo.2010.04.011 CrossRef

Jumper JM, Mittra RA (2011) Preferences and trends survey. Am Soc Retinal Specialists www.asrs.org/asrs-community/pat-survey. Accessed 14 Sep 2015

Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(1):43e1–58.e1. doi:10.1016/j.ajo.2009.01.024

10.

Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116(1):57.e5–65.e5. doi:10.1016/j.ophtha.2008.10.018 CrossRef

11.

Zweifel SA, Engelbert M, Laud K, Margolis R, Spaide RF, Freund KB (2009) Outer retinal tubulation: a novel optical coherence tomography finding. Arch Ophthalmol 127(12):1596–1602CrossRefPubMed

12.

Milam AH, Jacobson SG (1990) Photoreceptor rosettes with blue cone opsin immunoreactivity in retinitis pigmentosa. Ophthalmology 97(12):1620–1631CrossRefPubMed

13.

Tulvatana W, Adamian M, Berson EL, Dryja TP (1999) Photoreceptor rosettes in autosomal dominant retinitis pigmentosa with reduced penetrance. Arch Ophthalmol 117:399–402CrossRefPubMed

14.

Lee JY, Folgar FA, Maguire MG, Ying GS, Toth CA, Martin DF, Jaffe GJ, CATT Research Group (2014) Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 121(12):2423–2431. doi:10.1016/j.ophtha.2014.06.013 CrossRefPubMedPubMedCentral

15.

Gildener-Leapman JR, Srivistava S, Ehlers JP, Kaiser PK (2015) Prevalence of outer retinal tubulation after anti-VEGF therapy for age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 46(3):345–348. doi:10.3928/23258160-20150323-08 CrossRefPubMed

16.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548. doi:10.1016/j.ophtha.2012.09.006 CrossRefPubMed

17.

Jung JJ, Freund KB (2012) Long-term follow-up of outer retinal tubulation documented by eye-tracked and en face spectral-domain optical coherence tomography. Arch Ophthalmol 130(12):1618–1619. doi:10.1001/archophthalmol.2012.1902 CrossRefPubMed

18.

Goldberg NR, Greenberg JP, Laud K, Tsang S, Freund KB (2013) Outer retinal tubulation in degenerative retinal disorders. Retina 33(9):1871–1876. doi:10.1097/IAE.0b013e318296b12f CrossRefPubMedPubMedCentral

19.

Tulvatana W, Adamian M, Berson EL, Dryja TP (1999) Photoreceptor rosettes in autosomal dominant retinitis pigmentosa with reduced penetrance. Arch Ophthalmol 117(3):399–402CrossRefPubMed

20.

Wolff B, Matet A, Vasseur V, Sahel JA, Mauget-Faÿsse M (2012) En face OCT imaging for the diagnosis of outer retinal tubulations in age-related macular degeneration. J Ophthalmol 2012:542417. doi:10.1155/2012/542417 CrossRefPubMedPubMedCentral

21.

Spaide RF, Curcio CA (2011) Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina 31(8):1609–1619. doi:10.1097/IAE.0b013e3182247535 CrossRefPubMedPubMedCentral

22.

Espina M, Arcinue CA, Ma F, Camacho N, Barteselli G, Mendoza N, Ferrara N, Freeman WR (2015) Outer retinal tubulations response to anti-VEGF treatment. Br J Ophthalmol. doi:10.1136/bjophthalmol-2015-307141 PubMed

23.

Dirani A, Gianniou C, Marchionno L, Decugis D, Mantel I (2015) Incidence of outer retinal tubulation in ranibizumab-treated age-related macular degeneration. Retina 35(6):1166–1172. doi:10.1097/IAE.0000000000000439 CrossRefPubMed

24.

Coscas F, Coscas G, Lupidi M, Dirani A, Srour M, Semoun O, Français C, Souied EH (2015) Restoration of outer retinal layers after aflibercept therapy in exudative amd: prognostic value. Invest Ophthalmol Vis Sci 56(6):4129–4134. doi:10.1167/iovs.15-16735 CrossRefPubMed

25.

da Moon RC, Lee DK, Kim SH, You YS, Kwon OW (2015) Aflibercept treatment for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy refractory to anti-vascular endothelial growth factor. Korean J Ophthalmol 29(4):226–232. doi:10.3341/kjo.2015.29.4.226 CrossRefPubMedCentral

26.

Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I (2015) Factors influencing the treatment response of pigment epithelium detachment in age-related macular degeneration. Am J Ophthalmol 160(4):732.e2–738.e2. doi:10.1016/j.ajo.2015.06.025 CrossRef

Title: Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration
Authors: Nathalie Massamba
Ali Dirani
Nathalie Butel
Christine Fardeau
Bahram Bodaghi
April Ingram
Phuc Lehoang
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-016-3423-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Plasma E-selectin levels can play a role in the development of diabetic retinopathy

Serial optical coherence tomography angiography for corneal vascularization

FK962 induces neurite outgrowth in cultured monkey trigeminal ganglion cells

The role of microRNAs in myopia

Arginase activity, urea, and hydroxyproline concentration are reduced in keratoconus keratocytes

“Ant-egg” cataract revisited